The weapon is not a new medication but a ground-breaking computer-modelling tool.

About LEO Pharma LEO Pharma is an independent research based business with headquarters in Ballerup, Denmark. LEO Pharma is certainly 100 percent owned by the LEO Foundation and is normally a globally leading company within Dermatology and Vital Care. LEO Pharma includes a strong focus on developing, developing and marketing safe and efficacious medications for treating psoriasis and other skin diseases along with thromboembolic disorders. For further information, please visit.. A New Computer-Modelling Tool to Improve Psoriasis Administration and Treatment Outcomes At the 17th EADV Conference in Paris, LEO Pharma has unveiled a new weapon in its long-running campaign to improve psoriasis administration and treatment outcomes.This campaign will help physicians, patients and other healthcare experts address overuse of health care resources in the United States. The advertising campaign facilitates ABIM Foundation’s goal of improving health care outcomes and avoiding unnecessary and even dangerous interventions to be able to improve patient treatment and decrease the rapidly-expanding costs of the health care system. If current trends stay unchanged, the Centers for Medicare & Medicaid Solutions project U.S. Health care spending will reach $4.3 trillion by 2019. Related StoriesNxStage Program One now used in eight of Top 10 Nephrology Hospitals in the U.S.Price of radiation therapy varies broadly among Medicare patients with cancerGenomic Health announces Medicare insurance for Oncotype DX prostate cancer tumor testAs part of the marketing campaign, ASN has convened several specialists to develop a list of tests or procedures that kidney sufferers and physicians should issue and discuss.